Recent Updates
Recently added Catalysts
SIBN Positive Sentiment Score: 75/100

SI-BONE To Present at Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024

Key Takeaway: SI-BONE, Inc. will participate in the Morgan Stanley 22nd Annual Global Healthcare Conference on September 4, 2024. The company's management will host a fireside chat during the event, which will be accessible for investors through audio webcast. SI-BONE has a notable history in developing surgical treatments for sacropelvic disorders, having supported over 3,900 physicians and conducted over 100,000 procedures since 2009. This participation underscores the company's credibility in the healthcare sector.

Market Sentiment Analysis

POSITIVE FACTORS

  • SI-BONE is recognized as a global leader in surgical treatment technologies.
  • The company has a strong track record with over 100,000 procedures supported.
  • Participation in a prominent healthcare conference highlights SI-BONE's exposure and credibility.

Full Press Release Details

SANTA CLARA, Calif., Aug. 22, 2024 (GLOBE NEWSWIRE) -- SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving sacropelvic disorders, today announced that the company will be participating in the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference in New York. Management will be hosting a fireside chat on Wednesday, September 4, 2024, at 10:45 a.m. Eastern Time / 7:45 a.m. Pacific Time.
Investors interested in listening to the conference call may do so by registering at this link: https://url.us.m.mimecastprotect.com/s/r-x6CjRnDNsnPR3wF7sxumTszz?domain=cc.webcasts.com. Live audio of the webcast will be available on the “Investors” section of the company’s website at: www.si-bone.com. The webcast will be archived and available for replay for at least 90 days after the event.
SI-BONE (NASDAQ: SIBN) is a global leader in developing unique technologies for surgical treatment of sacropelvic disorders. Since pioneering minimally invasive SI joint surgery in 2009, SI-BONE has supported over 3,900 physicians in performing a total of over 100,000 procedures. A unique body of clinical evidence supports the use of SI-BONE’s technologies, including two randomized controlled trials and over 130 peer reviewed publications. SI-BONE has leveraged its leadership in minimally invasive SI joint fusion to commercialize novel solutions for adjacent markets, including adult deformity, spinopelvic fixation and pelvic trauma.
For additional information on the company or the products including risks and benefits, please visit www.si-bone.com.
Investor Contact: Saqib Iqbal investors@si-bone.com

Frequently Asked Questions

What is SI-BONE, Inc. known for?

SI-BONE specializes in technologies for treating sacropelvic disorders.

When will SI-BONE present at the Morgan Stanley Conference?

SI-BONE will present on September 4, 2024, at 10:45 a.m. ET.

How can investors listen to the conference call?

Investors can register and access the call through the provided link.

What significant milestones has SI-BONE achieved?

SI-BONE has supported over 3,900 physicians with 100,000 procedures since 2009.

Where can I find more information about SI-BONE?

Visit SI-BONE's website for detailed information about products and services.

Last updated: Aug 22, 2024